212 related articles for article (PubMed ID: 35581018)
1. Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Zhang Y; Zhang Y; Zhang B; Chen Z; Wei Y; Chen P; Chang C; Liu G; Chen K; Ding J; Jiang Z
Clin Ther; 2022 Jun; 44(6):901-912. PubMed ID: 35581018
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome.
Xu X; Chai M; Cheng Y; Peng P; Liu X; Yan Z; Guo Y; Zhao Y; Zhou Y
Curr Vasc Pharmacol; 2021; 19(4):429-437. PubMed ID: 32543364
[TBL] [Abstract][Full Text] [Related]
3. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
Hao Y; Yang YL; Wang YC; Li J
Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
[TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
5. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Koskinas KC; Windecker S; Pedrazzini G; Mueller C; Cook S; Matter CM; Muller O; Häner J; Gencer B; Crljenica C; Amini P; Deckarm O; Iglesias JF; Räber L; Heg D; Mach F
J Am Coll Cardiol; 2019 Nov; 74(20):2452-2462. PubMed ID: 31479722
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9.
Ferri N; Ruscica M; Lupo MG; Vicenzi M; Sirtori CR; Corsini A
Pharmacol Res; 2022 Oct; 184():106439. PubMed ID: 36100012
[TBL] [Abstract][Full Text] [Related]
7. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.
Furtado RHM; Fagundes AA; Oyama K; Zelniker TA; Tang M; Kuder JF; Murphy SA; Hamer A; Wang H; Keech AC; Giugliano RP; Sabatine MS; Bergmark BA
Circ Cardiovasc Interv; 2022 Mar; 15(3):e011382. PubMed ID: 35209731
[TBL] [Abstract][Full Text] [Related]
8. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR;
N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
[TBL] [Abstract][Full Text] [Related]
10. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
Murphy SA; Pedersen TR; Gaciong ZA; Ceska R; Ezhov MV; Connolly DL; Jukema JW; Toth K; Tikkanen MJ; Im K; Wiviott SD; Kurtz CE; Honarpour N; Giugliano RP; Keech AC; Sever PS; Sabatine MS
JAMA Cardiol; 2019 Jul; 4(7):613-619. PubMed ID: 31116355
[TBL] [Abstract][Full Text] [Related]
11. Long-term benefits of high-intensity atorvastatin therapy in Chinese acute coronary syndrome patients undergoing percutaneous coronary intervention: A retrospective study.
Liu H; Dong A; Wang H
Medicine (Baltimore); 2018 Oct; 97(42):e12687. PubMed ID: 30334951
[TBL] [Abstract][Full Text] [Related]
12. Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial.
Ishihara M; Asakura M; Hibi K; Okada K; Shimizu W; Takano H; Suwa S; Fujii K; Okumura Y; Mano T; Tsujita K; Igeta M; Okamoto R; Suna S
EuroIntervention; 2022 Oct; 18(8):e647-e655. PubMed ID: 35837711
[TBL] [Abstract][Full Text] [Related]
13. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
Zhao SP; Yu BL; Peng DQ; Huo Y
Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
[TBL] [Abstract][Full Text] [Related]
14. Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH).
Han Y; Ren L; Fei X; Wang J; Chen T; Guo J; Wang Q
Atherosclerosis; 2024 Apr; 391():117471. PubMed ID: 38493669
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Perioperative Use of Evolocumab in Myocardial Infarction Patients: Study Protocol for a Multicentre Randomized Controlled Trial.
Luan Y; Wang M; Zhao L; Xu T; Fu G; Zhang W
Adv Ther; 2021 Apr; 38(4):1801-1810. PubMed ID: 33638801
[TBL] [Abstract][Full Text] [Related]
16. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome.
Yano H; Horinaka S; Ishimitsu T
J Cardiol; 2020 Mar; 75(3):289-295. PubMed ID: 31495548
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke.
Zhang T; Zhang Y; Yang Y; Liao H; Li X; Liu R; Liu X; Yang L; Yue W
J Thromb Thrombolysis; 2024 Feb; 57(2):302-311. PubMed ID: 38063944
[TBL] [Abstract][Full Text] [Related]
19. Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.
Koskinas KC; Windecker S; Buhayer A; Gencer B; Pedrazzini G; Mueller C; Cook S; Muller O; Matter CM; Räber L; Heg D; Mach F;
Clin Cardiol; 2018 Dec; 41(12):1513-1520. PubMed ID: 30421481
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients.
Jin ZL; He T; Peng L; Wu XY; Fan D; Chen M; Fan YZ; Guo YL; Lu ZB; Wang HR
Curr Med Sci; 2023 Dec; 43(6):1206-1212. PubMed ID: 37755635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
